Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.62 USD | +11.97% | -2.24% | -19.75% |
Apr. 24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
Apr. 08 | Gain Therapeutics Names Gene Mack as CFO | MT |
Financials (USD)
Sales 2024 * | 425K | Sales 2025 * | 175K | Capitalization | 47.3M |
---|---|---|---|---|---|
Net income 2024 * | -21M | Net income 2025 * | -28M | EV / Sales 2024 * | 116 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 270 x |
P/E ratio 2024 * |
-2.47
x | P/E ratio 2025 * |
-2.18
x | Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.25% |
1 day | +11.97% | ||
1 week | -2.24% | ||
Current month | -10.58% | ||
1 month | -15.21% | ||
3 months | -45.42% | ||
6 months | -9.66% | ||
Current year | -19.75% |
Managers | Title | Age | Since |
---|---|---|---|
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Comptroller/Controller/Auditor | 35 | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dov Goldstein
BRD | Director/Board Member | 56 | 20-12-31 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 2.62 | +11.97% | 151,643 |
24-05-14 | 2.34 | -3.31% | 240,365 |
24-05-13 | 2.42 | -3.59% | 54,674 |
24-05-10 | 2.51 | -1.18% | 106,802 |
24-05-09 | 2.54 | -5.22% | 239,414 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.75% | 47.3M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.39% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- GANX Stock